CardiovascularThe world looks to the DCRI as the definitive leader in cardiovascular clinical research, implementation science, and education. We look to our practicing faculty, cutting-edge analytics, and operational expertise to address the spectrum of challenges through clinical research focused on improving the care of patients with cardiovascular disease.
The Next CV Advancement
The Cardiovascular Clinical Trials group advances and streamlines the process through innovative study design, fit-for-purpose approaches, thoughtful analytics, and a commitment to rapid knowledge dissemination. This is essential to translate novel therapeutic concepts into effective and efficient clinical trials across the spectrum of cardiovascular illnesses, including:
- Acute coronary syndromes
- Chronic coronary artery disease and coronary atherosclerosis
- Dyslipidemia and hyperlipidemia
- Cardiac surgery
- Cardiovascular genetics and genomics
- Cardiac diagnostic testing
- Atrial fibrillation
- Pacemakers and implantable defibrillators
- Antiarrhythmic agents
- Geriatric cardiology
- Heart failure
- Pediatric cardiology
- Peripheral vascular disease
- Diabetes mellitus and cardiovascular disease
- Metabolic disorders
- Risk modeling for coronary disease
- Valvular heart disease
CV Outcomes Research
Prove the Value of Better Patient Care
The demand to clearly and quickly demonstrate outcomes of new therapies for cardiovascular patients is greater now than ever before. And the DCRI is the national leader in helping sponsors do that—collecting and analyzing economic and quality-of-life data for the purpose of overcoming barriers to reimbursement.
DCRI’s Outcomes Research Group maintains the world’s oldest and largest ongoing database for cardiovascular disease and is conducting groundbreaking pragmatic clinical trials for patients with heart disease.
With 21 full-time faculty and 100 full-time statisticians, project managers, and research and operational team members, the DCRI Outcomes Research team evaluates outcomes and costs in phase II through IV clinical trials and observational research studies.
Real World Solutions
for Today's CV Challenges
Our cardiovascular expertise covers all research phases—from proof-of-concept studies to multinational late-phase trials. We also work with post-approval registries sponsored by industry, government, and professional societies. Most importantly, everything we learn is shared openly so that others can take our findings and build upon them, ensuring that the best answers to the hardest questions are found.
Review our capabilities, trials and outcomes projects, clinical event adjudication projects, networks, operational improvement programs, registries and quality improvement programs, and more.
Testing for Cardiovascular Devices
The DCRI has a team of experts specifically dedicated to providing critical guidance and support for the unique challenges faced by devices trials, such as evolving regulatory requirements and the need for rapid recruitment of eligible patients.
at the DCRI
John H. Alexander is a cardiologist and professor of medicine in the Department of Medicine and Division of Cardiology at Duke University, as well as the Vice Chief for Clinical Research in the Division of Cardiology. He is the director of cardiovascular research at the DCRI, where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and other clinical research programs.
Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research focuses on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes and chronic coronary artery disease, on antithrombotic therapies, and on novel methodological approaches to clinical research.
Alexander has published extensively and has served on the steering committee and as the principal investigator of numerous multicenter clinical trials. He serves on steering committee of the Clinical Trial Transformation Initiative (CTTI).